BACKGROUND: Short QT syndrome (QTc ≤ 300 ms) is a novel hereditary channelopathy linked to syncope, paroxysmal atrial fibrillation, and sudden cardiac death. However, its epidemiological features remain unsettled. OBJECTIVES: (1) To assess the prevalence of short QT in a large population-based sample; (2) to evaluate its demographic and clinical correlates and; (3) to determine its prognosis. METHODS: A database of 6.4 million electrocardiograms (ECGs) obtained between 1995 and 2008 among 1.7 million persons was used. An internal, population-based method for heart rate correction (QTcreg ) was used and all ECGs with QTcreg ≤300 ms were manually validated. Linked health plan databases were used for covariate and survival ascertainment. RESULTS: Of 6,387,070 ECGs, 1086 had an ECG with machine-read QTcreg ≤300 ms. Only 4% (45/1086) were validated yielding a prevalence of 0.7 per 100,000 or 1 of 141,935 ECGs. At the person level, the overall prevalence of QTcreg ≤300 ms was 2.7 per 100,000 or 1 of 37,335. The factors independently and significantly associated with validated QTcreg ≤300 ms were age over 65 years, Black race, prior history of ventricular dysrhythmias, chronic obstructive pulmonary disease, ST-T abnormalities, ischemia, bigeminy pattern, and digitalis effect. After 8.3 years of median follow-up and relative to normal QTcreg , validated QTcreg ≤300 ms was associated after multivariate adjustment with a 2.6-fold (95% confidence interval [CI] = 1.9-3.7) increased risk of death. CONCLUSION: QTcreg ≤300 ms was extraordinarily rare and was associated with significant ECG abnormalities and reduced survival.
BACKGROUND:Short QT syndrome (QTc ≤ 300 ms) is a novel hereditary channelopathy linked to syncope, paroxysmal atrial fibrillation, and sudden cardiac death. However, its epidemiological features remain unsettled. OBJECTIVES: (1) To assess the prevalence of short QT in a large population-based sample; (2) to evaluate its demographic and clinical correlates and; (3) to determine its prognosis. METHODS: A database of 6.4 million electrocardiograms (ECGs) obtained between 1995 and 2008 among 1.7 million persons was used. An internal, population-based method for heart rate correction (QTcreg ) was used and all ECGs with QTcreg ≤300 ms were manually validated. Linked health plan databases were used for covariate and survival ascertainment. RESULTS: Of 6,387,070 ECGs, 1086 had an ECG with machine-read QTcreg ≤300 ms. Only 4% (45/1086) were validated yielding a prevalence of 0.7 per 100,000 or 1 of 141,935 ECGs. At the person level, the overall prevalence of QTcreg ≤300 ms was 2.7 per 100,000 or 1 of 37,335. The factors independently and significantly associated with validated QTcreg ≤300 ms were age over 65 years, Black race, prior history of ventricular dysrhythmias, chronic obstructive pulmonary disease, ST-T abnormalities, ischemia, bigeminy pattern, and digitalis effect. After 8.3 years of median follow-up and relative to normal QTcreg , validated QTcreg ≤300 ms was associated after multivariate adjustment with a 2.6-fold (95% confidence interval [CI] = 1.9-3.7) increased risk of death. CONCLUSION: QTcreg ≤300 ms was extraordinarily rare and was associated with significant ECG abnormalities and reduced survival.
Authors: Sophia H Zhou; Eric D Helfenbein; James M Lindauer; Richard E Gregg; Dirk Q Feild Journal: Ann Noninvasive Electrocardiol Date: 2009-01 Impact factor: 1.468
Authors: Kui Hong; David R Piper; Aurora Diaz-Valdecantos; Josep Brugada; Antonio Oliva; Elena Burashnikov; José Santos-de-Soto; Josefina Grueso-Montero; Ernesto Diaz-Enfante; Pedro Brugada; Frank Sachse; Michael C Sanguinetti; Ramon Brugada Journal: Cardiovasc Res Date: 2005-08-18 Impact factor: 10.787
Authors: Juan Villafañe; Joseph Atallah; Michael H Gollob; Philippe Maury; Christian Wolpert; Roman Gebauer; Hiroshi Watanabe; Minoru Horie; Olli Anttonen; Prince Kannankeril; Brett Faulknier; Jorge Bleiz; Takeru Makiyama; Wataru Shimizu; Robert M Hamilton; Ming-Lon Young Journal: J Am Coll Cardiol Date: 2013-01-30 Impact factor: 24.094
Authors: Roberta Pereira; Oscar Campuzano; Georgia Sarquella-Brugada; Sergi Cesar; Anna Iglesias; Josep Brugada; Fernando E S Cruz Filho; Ramon Brugada Journal: Clin Res Cardiol Date: 2017-03-16 Impact factor: 5.460
Authors: Neha Mantri; Meng Lu; Jonathan G Zaroff; Neil Risch; Thomas Hoffmann; Akinyemi Oni-Orisan; Catherine Lee; Carlos Iribarren Journal: Ann Noninvasive Electrocardiol Date: 2021-09-21 Impact factor: 1.468
Authors: J S Floyd; C M Sitlani; C L Avery; R Noordam; X Li; A V Smith; S M Gogarten; J Li; L Broer; D S Evans; S Trompet; J A Brody; J D Stewart; J D Eicher; A A Seyerle; J Roach; L A Lange; H J Lin; J A Kors; T B Harris; R Li-Gao; N Sattar; S R Cummings; K L Wiggins; M D Napier; T Stürmer; J C Bis; K F Kerr; A G Uitterlinden; K D Taylor; D J Stott; R de Mutsert; L J Launer; E L Busch; R Méndez-Giráldez; N Sotoodehnia; E Z Soliman; Y Li; Q Duan; F R Rosendaal; P E Slagboom; K C Wilhelmsen; A P Reiner; Y-Di Chen; S R Heckbert; R C Kaplan; K M Rice; J W Jukema; A D Johnson; Y Liu; D O Mook-Kanamori; V Gudnason; J G Wilson; J I Rotter; C C Laurie; B M Psaty; E A Whitsel; L A Cupples; B H Stricker Journal: Pharmacogenomics J Date: 2016-12-13 Impact factor: 3.550